Ontology highlight
ABSTRACT:
PROVIDER: PRJNA887013 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR21800200.fastq.gz | Fastqsanger.gz | |||
| SRR21800300.fastq.gz | Fastqsanger.gz | |||
| SRR21800201.fastq.gz | Fastqsanger.gz | |||
| SRR21800301.fastq.gz | Fastqsanger.gz | |||
| SRR21800202.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 172 |
Similar Datasets
Project description:Skin bacteria impact melanoma related pathways Melanoma represents the most lethal form of skin cancer, with rising numbers of annual incidences worldwide. In an effort to identify new risk factors that promote melanoma development, the contribution of the skin microbiome gained increasing attention. Previous studies already demonstrated an altered composition of the skin microbiome on melanoma sites. Yet, the underlying mechanisms of the interplay between the microbiome and melanoma progression remain elusive. We established a novel co-culture system capable to study host microbiome interactions during melanoma progression in situ. This system consists of a commercial 3D melanoma skin model colonized with skin bacteria obtained from a skin swab of a healthy volunteer. The models showed a stable co-colonization over a period of 12 days, with Streptococcus being the most abundant genus on the last day of cultivation. Transcriptome profiles revealed significant differences in colonized models compared to control. In particular, pathways involved in melanoma progression, like RAF/MAP and PI3K kinase, were upregulated in colonized models. This correlates with the augmented release of the cytokines VEGF, PIGF, and GM-CSF as well as the typical melanoma markers MIA and S100B. Furthermore, the data were supported by an active epithelial-mesenchymal transition in colonized skin models. Taken together, the bacterial community seems to promote the progression of melanoma in our established system, hence we provide an elegant method to elucidate the microbiome’s impact on cancer development in situ.
2026-02-17 | GSE273669 | GEO
Project description:Epigenetic alterations play significant roles in the melanoma tumorigenesis and malignant progression. We profiled genome-wide promoter DNA methylation patterns of melanoma cells deribed from primary lesions of Radial Growrth phase (RGP) and Vertical Growth Phase (VGP), metastatic lesions, and primary normal melanocytes by interrogating 14,495 genes using Illumina bead chip technology. By comparative analysis of the promoter methylation profiles, we identified epigenetically silenced gene signatures that potentially associated with malignant melanoma progression. Bisulphite converted genomic DNA from a group of melanoma cells representing pathologic stages of melanoma progression (3 cell lines derived from RGP melanoma lesions, 4 cell lines derived from VGP lesions, and 3 melastatic melanomas) and normal human primary melanocytes isolated from lightly pigmented adult skin were hybridized to Illumina's Infinium HumanMethylation27 BeadChips
2013-12-20 | E-GEOD-53516 | biostudies-arrayexpress
Project description:One of the components of the tumor progression of melanoma of the skin is the formation of drug resistance. Chemotherapeutic agents can affect the cell cycle, DNA repair. By influencing melanoma cells of the BRO and SK-MEL-2 lines, the effect of a cytostatic drug on the genomic profile was determined
2022-01-27 | E-MTAB-11399 | biostudies-arrayexpress
Project description:Melanoma, originating from the malignant transformation of melanocytes, is the deadliest form of skin cancer. The incidence of primary cutaneous melanoma is increasing, with about 132,000 new cases annually. While early-stage melanoma can often be treated successfully with surgery, advanced melanoma remains challenging, necessitating new therapeutic targets. The MAPK pathway, particularly involving MEK and ERK, is critical in melanoma progression. PLEKHA4, a protein involved in cancer biology, has been identified as a key factor in melanoma cell proliferation and progression. Our study investigated the role of PLEKHA4 in regulating MAPK signaling and its impact on drug sensitivity in melanoma. Proteomic analysis, cell culture experiments, and various molecular techniques, including immunoblotting and quantitative proteomics, were employed to elucidate PLEKHA4’s function. Results indicates that PLEKHA4 is overexpressed in melanoma, promoting cell proliferation. PLEKHA4 knockdown induces apoptosis through the MAPK and cMyc pathway. enhances cMyc ubiquitination and degradation, suggesting a potential mechanism for its role in melanoma. These findings highlight PLEKHA4 as a significant player in melanoma progression and a potential target for therapeutic intervention.
2025-01-22 | PXD053608 | Pride
Project description:The identification of novel tumor-specific markers may improve understanding of melanoma progression and prognostic accuracy. Whole genome expression profiling of 46 primary melanomas, 12 metastases, and 16 normal skin samples using Affymetrix U133 PLUS 2.0 array generated gene lists including both known and new melanoma genes. The molecular genetic alterations contributing to the pathogenesis of melanoma are incompletely defined and few independent prognostic features have been identified beyond the pathologic characteristics of the primary tumor. Early stage melanoma is frequently curable, in contrast to the inferior prognosis of melanomas with regional lymph nodes involvement and the incurability of distant metastatic disease. The identification of novel tumor-specific markers may improve our understanding of melanoma progression and prognostic accuracy. To find differentially expressed genes that can distinguish melanoma from normal tissue, we performed a whole genome expression profiling of 46 primary melanoma samples, 12 regional or distant metastases, and 16 normal skin samples using Affymetrix U133 2.0 Plus array. Our study generated lists of differentially expressed genes in melanoma and identified novel prognostic marker HMGA2. It is a novel, highly overexpressed melanoma gene associated with poor prognosis. The overexpression of HMGA2 is strongly associated with regional and distant metastases and serves as an independent predictor of disease-free survival and overall survival in melanoma. Melanoma samples were obtained through an IRB-approved protocol using informed consent at the University of Michigan Multidisciplinary Melanoma Clinic. A portion of pigmented lesions clinically suspicious for melanoma and known melanoma were sampled by punch biopsy at the time of excision. The punch biopsy was bisected; half was sent to for clinical diagnosis and the other half along with adjacent normal skin when available immediately snap-frozen in liquid nitrogen. Snap-frozen tissue was embedded in OCT (TissueTek) followed by frozen sectioning and H&E slide preparation. The slides were evaluated by dermatopathologist who identified areas with greater than 70% tumor cellularity, which were sampled for RNA extraction. Primary melanomas and melanoma metastases were derived from different patients. Metastatic samples included lymph nodes (n=8), subcutaneous soft tissue (n=2), spleen (n=1), and small intestine (n=1).
2012-06-07 | E-GEOD-15605 | biostudies-arrayexpress
Project description:Malignant melanoma is the most aggressive form of skin cancer therefore it is crucial to disclose its underlying molecular mechanisms. MicroRNAs are small endogenous non-coding RNAs able to post-transcriptionally down-regulate the expression of direct target genes. Using a melanoma progression model, we identified miR-146a as a key double-acting player in melanoma malignancy. In fact, miR-146a is able to enhance tumor growth while it suppresses dissemination. We evidenced that melanoma cell growth is coordinated by its direct target lunatic fringe (LFNG) which operates on the NOTCH/PTEN/Akt pathway. Instead, metastasis formation inhibition is linked to decreased expression of ITGAV and ROCK1. Relevantly, miR-146a expression correlates with melanoma recurrence and it is enriched both in patients-derived melanoma and cutaneous metastasis samples, while its direct targets are depleted. However, miR-146a levels drop in Circulating Tumor Cells, suggesting the necessity for miR-146a expression to fluctuate during tumor progression in order to favor tumor growth and allow dissemination. This study reconciles the contradictory biological functions of miR-146a in melanoma progression and unravels distinct molecular mechanisms that need to be considered for therapeutic interventions.
2016-03-18 | GSE77090 | GEO
Project description:The skin Microbiome stratifies Patients with CTCL into two subgroups. One subgroup has a balanced microbiome, while the other subgroups has a skin dybiosis with S. aureus outgrowth. This is accompanied by impaired TCR repertoire and poor clinical outcome.
2023-12-01 | GSE218874 | GEO
Project description:The skin Microbiome stratifies Patients with CTCL into two subgroups. One subgroup has a balanced microbiome, while the other subgroups has a skin dybiosis with S. aureus outgrow. This is accompanied by impaired TCR repertoir and poor clinical outcome.
2023-12-01 | GSE221149 | GEO